Yayın:
Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2

dc.contributor.authorGolcuk, Mert
dc.contributor.authorYildiz, Ahmet
dc.contributor.authorGur, Mert
dc.contributor.ituauthorGür, Mert
dc.date.accessioned2026-01-26T01:14:28Z
dc.date.issued2021-12-07
dc.description.abstractABSTRACTSARS-CoV-2 infection is initiated by binding of the receptor-binding domain (RBD) of its spike glycoprotein to the peptidase domain (PD) of angiotensin-converting enzyme 2 (ACE2) receptors in host cells. Recently detected Omicron variant of SARS-CoV-2 (B.1.1.529) is heavily mutated on RBD. Currently, the most common Omicron variants are the original BA.1 Omicron strain and the BA.2 variant, which became more prevalent since it first appeared. To investigate how these mutations affect RBD-PD interactions, we performed all-atom molecular dynamics simulations of the BA.1 and BA.2 RBD-PD in the presence of full-length glycans, explicit water and ions. Simulations revealed that RBDs of BA.1 and BA.2 variants exhibit a more dispersed interaction network and make an increased number of salt bridges and hydrophobic interactions with PD compared to wild-type RBD. Although BA.1 and BA.2 differ in two residues at the RBD-ACE2 interface, no major difference in RBD-PD interactions and binding strengths were observed between these variants. Using the conformations sampled in each trajectory, the Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) method estimated ~34% and ~51% stronger binding free energies for BA.1 and BA.2 RBD, respectively, than wild-type RBD, which may result in higher binding efficiency of the Omicron variant to infect host cells.
dc.description.urihttps://doi.org/10.1016/j.jmgm.2022.108286
dc.description.urihttps://doi.org/10.1101/2021.12.06.471377
dc.description.urihttps://www.biorxiv.org/content/biorxiv/early/2021/12/10/2021.12.06.471377.full.pdf
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/35964366
dc.description.urihttp://dx.doi.org/10.1016/j.jmgm.2022.108286
dc.identifier.doi10.1016/j.jmgm.2022.108286
dc.identifier.issn1093-3263
dc.identifier.openairedoi_dedup___::b8733eafcd6987f317f34539ba06f487
dc.identifier.orcid0000-0001-5476-8160
dc.identifier.orcid0000-0003-4792-174x
dc.identifier.orcid0000-0003-0983-4397
dc.identifier.startpage108286
dc.identifier.urihttps://hdl.handle.net/11527/55677
dc.identifier.volume117
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.ispartofJournal of Molecular Graphics and Modelling
dc.rightsOPEN
dc.sdg.typeGoal 3: Good Health and Well-being
dc.subjectSARS-CoV-2
dc.subjectMutation
dc.subjectSpike Glycoprotein, Coronavirus
dc.subjectCOVID-19
dc.subjectHumans
dc.subjectReceptors, Virus
dc.subjectAngiotensin-Converting Enzyme 2
dc.subjectArticle
dc.subjectProtein Binding
dc.titleOmicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2
dc.typeArticle
dspace.entity.typePublication
person.identifier.orcid0000-0003-0983-4397

Dosyalar

Koleksiyonlar